Global GMP Plasmid DNA Manufacturing Market Size is valued at USD 212.1 Million in 2024 and is predicted to reach USD 512.1 Million by the year 2034 at a 9.3% CAGR during the forecast period for 2025-2034.
Modern medicine heavily relies on plasmid DNA (PDNA). Plasmid DNA can be utilized either explicitly for a variety of therapeutic purposes, including gene therapy and the production of vaccine antigens, or indirectly for a broad range of research purposes. It is anticipated that the need for innovation in current manufacturing methods to meet the demand for acceptable products and their volume would offer substantial growth prospects for market players. A significant reason that propels the expansion of the GMP plasmid DNA manufacturing market is the rising number of gene therapy patients who choose to undergo the procedure.
The market for GMP plasmid DNA manufacturing will also benefit from growing government spending in the healthcare industry and an increase in older people. Plasmid DNA is in higher demand due to the need for effective illness treatment therapies. As a result, numerous businesses and research institutions are stepping up their R&D for cutting-edge treatments that target the disease's genomic origins. Due to the expanding research applications in genetic vaccination and gene therapy sectors, the market for GMP plasmid DNA manufacturing is expanding. The market is increasing favorably as more people are turning to gene therapy.
Several disorders may benefit from new potential treatments that gene therapy, a rapidly growing science, may provide. The increasing number of ties or collaborations between the different firms participating in this sector, which is anticipated to fuel the market growth, emphasizes the renewed interest in the manufacturing of plasmid deoxyribonucleic acid (DNA).
The GMP plasmid DNA manufacturing market is segmented based on products, types and applications. Based on Products, the market is segmented into Viral Vectors (Retroviral, Adenoviral, Lentiviral, Adeno-Associated, Others), Plasmid DNA, Non-viral, Lipid/polymer, Electroporation, Nanoparticles, and Others.Based on types, the market is segmented as pre-clinical therapeutics, clinical therapeutics, and marketed therapeutics. By application, the market is segmented into gene therapy, dan vaccines, immunotherapy, and others.
The clinical therapy category is expected to hold a major share of the global GMP plasmid DNA manufacturing market over the forecast period. Numerous plasmid DNA-based treatments are quickly moving past the clinical trial stage and will soon be available for purchase. The prevention or treatment of multiple illnesses, including cardiovascular diseases (CVDs) and cancer, including symptomatic patients, myeloid, acute ischemic, renal cell carcinoma, and coronary heart diseases, is being studied in current clinical studies based on plasmid DNA. Additionally, the role of plasmid DNA in clinical research implications for gene therapy and genetic vaccination is growing.
The gene therapy segment is projected to increase in the global GMP plasmid DNA manufacturing market. Gene therapy is used to alter cells and repair genetic material that is naturally flawed. Genetic problems have been successfully treated with cell and gene therapy. Gene therapies can also aid in diagnosing human viral illnesses and disorders. Additionally, the development of trustworthy and secure treatments for various ailments due to ongoing technological advancements is fueling the expansion of this market.
The North American GMP plasmid DNA manufacturing market is expected to register the highest market share in revenue soon. Increases in cancer patients, the desire for safe and effective medical procedures, and the existence of major market participants are the main factors propelling market expansion in the North American area. The GMP plasmid DNA manufacturing market will also be boosted by expanding technical advancements in the healthcare industry and newly discovered information on the use of plasmid DNA.
In addition, Asia Pacific is projected to grow rapidly in the global GMP plasmid DNA manufacturing market. Plasmid DNA manufacturing in the region will increase due to the region's aging population, increased disease rates among patients and the government's attempt to use plasmid DNA-based products.
|
Report Attribute |
Specifications |
|
Market Size Value In 2024 |
USD 212.1 Million |
|
Revenue Forecast In 2034 |
USD 512.1 Million |
|
Growth Rate CAGR |
CAGR of 9.3% from 2025 to 2034 |
|
Quantitative Units |
Representation of revenue in US$ Mn,and CAGR from 2025 to 2034 |
|
Historic Year |
2021 to 2024 |
|
Forecast Year |
2025-2034 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
Product, Type, Application |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Thermos Fisher Scientific, Cobra Bio, Rescript Probe, Wuxi Advanced Therapies, Charles River, Weisman Biomanufacturing, Bioscience, Lake Pharma, Alderton, Kaneka Neurogenetic S.A., Catalent Biologics, Neurogenetic, Nature Technology Corporation, Vector Builder, VGXI, Inc, Plasmid Factory, Delphi Genetics, Esko Aster, Bionian, Creative Biolabs, Vilene Biosciences, Patheon, Cognate Bio Services.. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global GMP Plasmid DNA Manufacturing Market Snapshot
Chapter 4. Global GMP Plasmid DNA Manufacturing Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Product Estimates & Trend Analysis
5.1. By Product & Market Share, 2024 & 2034
5.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Product:
5.2.1. Viral Vectors
5.2.1.1. Retroviral
5.2.1.2. Adenoviral
5.2.1.3. Lentiviral
5.2.1.4. Adeno-Associated
5.2.1.5. Others
5.2.2. Plasmid DNA
5.2.3. Non-viral
5.2.4. Lipid/polymer
5.2.5. Electroporation
5.2.6. Nanoparticles
5.2.7. Others
Chapter 6. Market Segmentation 2: By Type Estimates & Trend Analysis
6.1. By Type & Market Share, 2024 & 2034
6.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Type:
6.2.1. Pre-Clinical Therapeutics
6.2.2. Clinical Therapeutics
6.2.3. Marketed Therapeutics
Chapter 7. Market Segmentation 3: By Application Estimates & Trend Analysis
7.1. By Application & Market Share, 2024 & 2034
7.2. Market Size (Value (US$ Mn) & Forecasts and Trend Analyses, 2021 to 2034 for the following by Application:
7.2.1. Gene Therapy
7.2.2. DNA Vaccines
7.2.3. Immunotherapy
7.2.4. Others
Chapter 8. GMP Plasmid DNA Manufacturing Market Segmentation 4: Regional Estimates & Trend Analysis
8.1. North America
8.1.1. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.1.2. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.1.3. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.1.4. North America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.2. Europe
8.2.1. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.2.2. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.2.3. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.2.4. Europe GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.3. Asia Pacific
8.3.1. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.3.2. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.3.3. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.3.4. Asia Pacific GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.4. Latin America
8.4.1. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.4.2. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.4.3. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.4.4. Latin America GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
8.5. Middle East & Africa
8.5.1. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Product, 2021-2034
8.5.2. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Type, 2021-2034
8.5.3. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by Application, 2021-2034
8.5.4. Middle East & Africa GMP Plasmid DNA Manufacturing Market Revenue (US$ Million) Estimates and Forecasts by country, 2021-2034
Chapter 9. Competitive Landscape
9.1. Major Mergers and Acquisitions/Strategic Alliances
9.2. Company Profiles
9.2.1. Patheon (Thermo Fisher Scientific)
9.2.2. Cobra Bio
9.2.3. GenScript ProBio
9.2.4. WuXi Advanced Therapies
9.2.5. Charles River
9.2.6. Waisman Biomanufacturing
9.2.7. BioXcellence
9.2.8. LakePharma
9.2.9. Aldevron
9.2.10. Kaneka Eurogentec S.A.
9.2.11. Catalent Biologics
9.2.12. Eurogentec
9.2.13. Nature Technology Corporation
9.2.14. VectorBuilder
9.2.15. VGXI, Inc
9.2.16. PlasmidFactory
9.2.17. Delphi Genetics (Catalent)
9.2.18. Esco Aster
9.2.19. Biovian
9.2.20. Creative Biolabs
9.2.21. Vigene Biosciences (Charles River)
9.2.22. Cognate BioServices (Charles River)
9.2.24. Other Prominent Players
Based on Products
Based on Types
Based on Applications
By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
Rest of Middle East and Africa
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
